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Abstract

Author Manuscript
Author Manuscript

Repeated haloperidol and olanzapine treatment produces an enhanced disruption of avoidance
responding, a validated measure of antipsychotic activity. Experimental parameters affecting this
sensitization-like effect have not been thoroughly examined. The present study investigated the
role of three parameters (number of injections, dose, and interval between initial exposure and
challenge) in antipsychotic sensitization in the conditioned avoidance response paradigm. Welltrained Sprague–Dawley rats received different numbers of drug treatment (1–5 days) or different
doses of haloperidol (0.025–0.10 mg/kg, subcutaneously) or olanzapine (0.5–2.0 mg/kg,
subcutaneously). After certain time intervals (4, 10 or 17 days), they were tested for the expression
of haloperidol or olanzapine sensitization in a challenge test in which all rats were injected with a
lower dose of haloperidol (0.025 mg/kg) or olanzapine (0.5 mg/kg). Throughout the drugtreatment period, both haloperidol and olanzapine dose-dependently enhanced their disruption of
avoidance responding. Three days later, the sensitization induced by a low dose of haloperidol
(0.025 mg/kg) or olanzapine (0.5 mg/kg) was only apparent in rats that received treatment for 5
days, but not in those that received treatment for 1–4 days. The sensitization induced by the
medium and high doses of haloperidol (0.05 and 0.10 mg/kg) or olanzapine (1.0 and 2.0 mg/kg)
was still robust even with only 3 days of treatment. The sensitization induced by a 3-day
haloperidol (0.10 mg/kg) and olanzapine (2.0 mg/kg) treatment was long-lasting, still detectable
17 days after the last drug treatment. This study suggests that antipsychotic sensitization is a
robust behavioral phenomenon. Its induction and expression are strongly influenced by parameters
such as number of drug exposures, drug dose, and test–retest interval. Given the importance of
antipsychotic sensitization in the maintenance of antipsychotic effects in the clinic, this study
introduces a paradigm that can be used to investigate the behavioral and neurobiological
mechanisms underlying antipsychotic sensitization.
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Sensitization is a phenomenon often associated with repeated exposure to many
psychoactive drugs, such as cocaine, amphetamine, ethanol, nicotine, phencyclidine, and
morphine (Robinson and Becker, 1986; Kalivas and Stewart, 1991; Stewart et al., 1993;
Vanderschuren and Kalivas, 2000; Siuciak et al., 2006; Richtand et al., 2007; Vezina, 2007).
Sensitization is commonly described as an increase in the behavioral response to a
subsequent administration of a drug following a previous exposure to that particular drug
(Meririnne et al., 2001). Antipsychotic drugs, as medications for the treatment of
schizophrenia, can also induce various clinically-relevant sensitization effects, therapeutic as
well as side-effects (Emmett-Oglesby and Goudie, 1989), as a result of the brain’s adaptive
responses to long-term antipsychotic drug treatment (Konradi and Heckers, 2001; Schmitt et
al., 2004). Supersensitivity psychosis, tardive dyskinesia, and time-dependent sensitization
induced by antipsychotic treatment are some better-known clinical examples (Antelman et
al., 2000; Fallon and Dursun, 2011).
Although extensive researches have been carried out on sensitization induced by
psychotomimetic drugs, the behavioral and neurobiological mechanisms involved in
antipsychotic-induced sensitization are less understood. This lack of research on the
properties of antipsychotic sensitization is unexpected, given the fact that antipsychotics,
such as drugs of abuse, are often taken repeatedly for a prolonged period of time, and
antipsychotic sensitization is believed to be an important mechanism supporting the
maintenance of antipsychotic efficacy (Remington and Kapur, 2010).

Author Manuscript

In recent years, we have used the conditioned avoidance response (CAR) model, a wellestablished animal model with high predictive validity for antipsychotic action (Wadenberg
and Hicks, 1999), to investigate the long-term effects of repeated antipsychotic treatment (Li
et al., 2004b, 2007, 2009a, 2009b, 2010; Mead and Li, 2010). We showed that repeated
treatment with haloperidol (HAL; a typical antipsychotic), olanzapine (OLZ), and
risperidone (atypical antipsychotics) produces a progressively-enhanced disruption of
avoidance responding over 7 days (Li et al., 2007). This sensitization effect can also be
demonstrated in a subsequent challenge test (i.e. re-exposure to the drug) in which
antipsychotic-treated animals exhibit a stronger response (i.e. lower avoidance) to the drug
compared with the drug-naive animals (Mead and Li, 2010; Zhang and Li, 2012). It is also
long-lasting, producing an effect that can be seen up to 3 weeks later (Mead and Li, 2010)
and is subject to contextual and behavioral controls (Zhang and Li, 2012).

Author Manuscript

Despite the well-documented antipsychotic sensitization in the CAR model, the parametric
conditions in which sensitization occurs have not been clearly delineated. Several factors,
including the schedule of administration, drug doses, and the interval between the initial
injection and subsequent tests are known to have an impact on the magnitude of
psychomotor sensitization to drugs of abuse (Carey and DeVeaugh-Geiss, 1984; Robinson,
1984; Robinson and Becker, 1986; Kline et al., 1998; Antelman et al., 2000; Vezina, 2004).
How these parameters affect the strength of antipsychotic sensitization has not been
systematically investigated. Previous studies indicate that the drug-treatment schedule does
affect the long-term behavioral effects of a drug. For example, Samaha et al. (2007) reported

Behav Pharmacol. Author manuscript; available in PMC 2016 February 17.

Swalve and Li

Page 3

Author Manuscript

that the continuous administration of HAL through minipumps induces behavioral tolerance
in the CAR model, whereas our laboratory found that an intermittent administration of HAL
through daily injections produces sensitization (Mead and Li, 2010), Our own work also
suggests that the strength of OLZ-induced sensitization may depend on the number of prior
injections. In one study (Li et al., 2010), we found that rats that were treated with OLZ (1.0
mg/kg, subcutaneously) for 3 days showed a relatively less robust sensitization effect
compared to those who were treated with the drug for 5–7 days in other studies (Li et al.,
2007, 2009a; Mead and Li, 2010).
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This study represents the first attempt to comprehensively assess in a single study how
different experimental parameters affect antipsychotic sensitization in the CAR model, by
determining the number of exposures necessary to develop sensitization (experiments 1 and
2), the possible dose-dependent nature of this effect (experiments 3 and 4), and the length of
sensitization after the final drug administration (experiments 5 and 6). We also examined the
similarities and differences between typical (e.g. HAL) and atypical antipsychotics (e.g.
OLZ), which have different neuroreceptor binding profiles (Miyamoto et al., 2005), as
potential parallels or discrepancies between these two drug types could lead to an insight
into the mechanisms behind antipsychotic sensitization. On the basis of a review of the
literature on psychomotor sensitization, we hypothesized that HAL and OLZ sensitization
would be more prominent following a greater number of drug exposures, higher doses of the
drugs, and a shorter time interval. With regard to the time-interval effect, it is also possible
that antipsychotic sensitization would be stronger with a longer test–retest interval because
of the influence of ‘time-dependent sensitization’, referring to the observation that a brief
exposure to an antipsychotic drug induces a clinical effect that grows with the passage of
time (Antelman et al., 2000).
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Methods
Subjects
Male Sprague–Dawley rats (226–250 g upon arrival; Charles River, Portage, Michigan,
USA) were pair-housed in 48.3 × 26.7 × 20.3 cm transparent polycarbonate cages under 12h light/dark conditions (lights off between 18:00 and 06:00 h). All tests were carried out
during the light cycle. Room temperature was maintained at 22±1° with a relative humidity
of 45–60%. Food and water were freely available. Animals were habituated to the animal
facility for 5 days. All procedures were approved by the Institutional Animal Care and Use
Committee at the University of Nebraska-Lincoln.
Avoidance conditioning apparatus

Author Manuscript

Eight identical two-way shuttle boxes custom designed and manufactured by Med
Associates (St Albans, Vermont, USA) were used as testing apparatuses. Each box was
housed in a ventilated, sound-insulated isolation cubicle (96.5 cm width × 35.6 cm depth ×
63.5 cm height). Each box was 64 cm long, 30 cm high (from grid floor), and 24 cm wide,
and was divided into two equal-sized compartments by a partition with an arch style
doorway (15 cm high × 9 cm wide at base). A barrier (4 cm high) was placed between the
two compartments. The grid floor consisted of 40 stainless-steel rods with a diameter of 0.48
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cm, spaced 1.6 cm apart center to center, through which a scrambled footshock
[unconditioned stimulus (US) 0.8 mA, maximum duration 5 s] was delivered by a constantcurrent shock generator (model ENV-410B; Med Associates Inc., St Albans, Vermont,
USA) and scrambler (model ENV-412; Med Associates Inc.). The location of the rat, motor
activity (photobeam breaks), and crossings between compartments were monitored
constantly by a set of 16 photobeams (ENV-256-8P; Med Associates Inc.) at the bottom of
the box (3.5 cm above the grid floor). Illumination was provided by two house lights fixed
to the top of each compartment. The conditioned stimulus (CS, 76 dB white noise) was
produced by a speaker (ENV-224 AMX; Med Associates Inc.) mounted on the ceiling of the
cubicle, centered above the shuttle box. Background noise (~74 dB) was provided by a
ventilation fan fixed at the top corner of each isolation cubicle. All training, habituation, and
testing procedures were controlled by a personal computer with MED-PC interfacing
software (Med Associates Inc.).

Author Manuscript
Author Manuscript

Experiment 1: Effect of number of injections on haloperidol sensitization—
Experiment 1 was designed to test the number of drug exposures necessary to induce robust
sensitization (Fig. 1 for the experimental design). Sixty-four rats (divided into two batches)
were used. First, all rats were handled for 2 min daily and habituated to the testing chamber
for a total of 2 days (30 min/day, habituation program). After habituation, they were trained
to acquire CAR daily for 10 days. Each training session consisted of 30 trials (intertrial
intervals on a variable interval schedule between 30 and 60 s). Each trial began with a
presentation of white noise (CS) for 10 s, followed by a continuous scrambled footshock
(0.8mA, US, maximum duration 5 s) on the grid floor where the rat was located. If the rat
crossed the compartments within the 10-s CS presentation, it would avoid the shock
(recorded as an avoidance). If the rat crossed only after receiving the shock presentation, this
was recorded as an escape. If the rat did not switch compartments during the presentation of
the shock (5 s), shock was discontinued, and an escape failure was recorded.

Author Manuscript

At the end of the training session, 48 rats had reached the training criterion (at least 70%
avoidance on day 10 of training) and were used in the subsequent drug tests. They were
matched for performance level (number of avoidances on day 10) and then semirandomly
assigned (randomly assigned based on the matched groups) into one of the six treatment
groups (n=8/group) based on the number of days of HAL exposure: vehicle (VEH) or HAL
for 1–5 days (HAL1, HAL2, HAL3, HAL4, and HAL5). In the next 5 days, the rats were
repeatedly tested in the CAR apparatus under a CS-only condition (presentation of tone not
followed by shock, 30 trials/session). The CS-only condition was used as a way to prevent
relearning and eliminating the potential confound of number of shocks received. On each
day, the groups received an injection of either HAL (0.025 mg/kg) or VEH (sterile water)
and were placed in the boxes and tested 1 h later. The HAL5 group received an injection of
HAL on each of the 5 days, whereas the HAL1, HAL2, HAL3, and HAL4 groups received
the corresponding number of drug exposures; for example, the HAL2 group was injected
with VEH for the first 3 days of exposure and HAL on the fourth and fifth day.
One day after the last drug test, all rats were tested drug-free for one session under the CSonly condition and retrained for one session under the CS–US condition to bring their
avoidance back to predrug level. The first CS-only session was used to examine any
Behav Pharmacol. Author manuscript; available in PMC 2016 February 17.
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potential carryover effects of the drug. A final drug-challenge test was conducted 24 h after
the retraining session to assess sensitization. The test days were identical to the exposure
days, with an injection of 0.025 mg/kg HAL 1 h before a CS-only 30-trial session.
Experiment 2: Effect of number of injections on olanzapine sensitization—
Experiment 2 was identical to experiment 1, except that HAL (0.025 mg/kg) was replaced
by OLZ (0.5 mg/kg). Sixty-four rats were trained to the criterion level, of which 48 rats were
used. Following the group-assigning procedure as described in experiment 1, they were
assigned to six groups (n=8/group): VEH, and OLZ for 1–5 days (OLZ1, OLZ2, OLZ3,
OLZ4, and OLZ5), and were subjected to five sessions of drug testing and two sessions of
drug-free testing/retraining and a final drug-challenge test. During the challenge test, all rats
were tested with OLZ (0.5 mg/kg, subcutaneously).
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Experiment 3: Effect of haloperidol dose on the strength of antipsychotic
sensitization effect—Experiment 3 was conducted to determine whether the HAL
sensitization effect was dose-dependent (Fig. 2). The procedure used in this experiment was
similar to that of experiment 1. Forty rats were handled and habituated for 2 days and trained
for 10 days in the CAR apparatus. Thirty-two rats reached the training level and were
matched and assigned into four groups: VEH, low-dose HAL group (0.025 mg/kg), mediumdose HAL group (0.05 mg/kg), and a high-dose HAL group (0.1 mg/kg). We tested three
doses of HAL, which covered subclinical, clinical, and superclinical doses in terms of
dopamine D2 receptor occupancy (50–80%; Kapur et al., 2003). Rats were then injected
with VEH or HAL 1 h before being tested in the CAR box under the CS-only condition for a
total of 3 days. This was followed by 2 days of rest when the rats remained in the home
cage, followed by one session of drug-free testing and one session of retraining. After the
retraining session, all rats went through a final challenge session and were injected with a
low dose of HAL (0.025 mg/kg).
Experiment 4: Effect of olanzapine dose on the strength of antipsychotic
sensitization effect—In this experiment, OLZ was tested. Forty Sprague–Dawley rats
were handled and habituated for 2 days (30min/day). Four groups (n=8/group) of rats (VEH,
low-dose OLZ 0.5mg/kg, medium-dose OLZ 1.0 mg/kg, and high-dose OLZ 2.0 mg/kg)
were tested. These doses of OLZ have been shown to produce disrupted avoidance measures
(Li et al., 2004b) and give rise to 50–80% dopamine D2 receptor occupancy (Kapur et al.,
2003). During the drug-challenge test, all rats were injected with OLZ at 0.5mg/kg.
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Experiment 5: Effect of time interval between initial haloperidol exposure and
re-exposure on the strength of haloperidol sensitization—Experiment 5 examined
the longevity of HAL sensitization. The interval between the initial drug treatment sessions
and the challenge days was manipulated (e.g. 4, 10, and 17 days) while maintaining the dose
and number of the HAL treatment constant (Fig. 3). Forty-eight rats that had fulfilled the
criterion previously (in two batches, out of an initial 64 that were trained) were divided into
six groups (n=8/group): two 4-day groups (VEH–HAL4 and HAL–HAL4), two 10-day
groups (VEH–HAL10 and HAL–HAL10) and two 17-day groups (VEH–HAL17 and HAL–
HAL17). All rats were first tested under VEH (sterile water) or HAL (0.1 mg/kg) for 3 days.
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They then went through 1, 7, or 14 days of rest, followed by 1 day of retesting in a CS-only
condition and 1 day of retraining. This was followed by a challenge day when all rats were
injected with HAL (0.025 mg/kg) 1 h before sensitization testing. During the rest interval,
rats remained in their home cages.
Experiment 6: Effect of time interval between initial olanzapine exposure and
re-exposure on the strength of olanzapine sensitization—This experiment tested
the longevity of OLZ (2.0 mg/kg) sensitization using an identical procedure to experiment 5.
Forty-eight rats that had previously met criterion (in two batches, out of an initial 64 that
were trained) were chosen, matched, and assigned into six groups (n= 8/group): VEH–
OLZ4, VEH–OLZ10, VEH–OLZ17, OLZ–OLZ4, OLZ–OLZ10, and OLZ–OLZ17. On the
challenge day, all rats were injected with OLZ (0.5mg/kg) 1 h before sensitization testing.

Author Manuscript

Drugs
The injection solution of HAL (5.0 mg/ml Ampoules, Shanghai Xudong Haipu
Pharmaceutical Co. Ltd, Shanghai, China) was obtained by mixing drugs with sterile water.
OLZ (a gift from the NIMH drug supply program) was dissolved in 1.0% glacial acetic acid
in distilled water. Both drugs were administered subcutaneously in a volume of 1.0 ml/kg
body weight. Drug doses for HAL and OLZ were based on previous studies showing that at
the chosen doses, both drugs produce a reliable disruption of avoidance responding while
not producing significant motor impairment (Li et al., 2004a, 2009a, 2009b; Mead and Li,
2010; Zhang and Li, 2012).
Statistical analysis

Author Manuscript

All data are expressed as mean±SEM. Data from the drug exposure sessions were analyzed
using a split-plot repeated-measures analysis of variance (ANOVA) with the betweensubjects factor drug group and the within-subjects factor test session. Data from the
challenge sessions were analyzed using either a one-way or a two-way ANOVA. Planned
comparisons were used to determine specific group differences. Block data were also
analyzed using either a one-way or two-way ANOVA (daily trials were split into three
batches and analyzed by 10-trial blocks), followed by least significant difference (LSD)
post-hoc tests. A conventional α value of 0.05 was used to determine significance. All data
were analyzed using SPSS version 17 (SPSS Inc., Armonk, New York, USA).

Results
Experiment 1: Effect of number of injections on haloperidol sensitization

Author Manuscript

As Figure 4a shows, although the VEH group maintained a high level of avoidances (>85%
avoidances over the 5 days of VEH treatment), those that had been exposed to HAL showed
lower levels of avoidances. A repeated-measures ANOVA revealed significant main effects
of Drug Group [F(5,50)=23.40, P<0.001] and Session [F(4,200)=102.734 P<0.001] and a
significant Group × Session interaction [F(20,200)=7.33, P<0.001], suggesting that the
groups that had more than one exposure to the drug (HAL2, HAL3, HAL4, and HAL5)
displayed a progressive across-session decrease in avoidance levels (Fig. 4a). During the
two drug-free testing/retraining days, the avoidance levels returned to predrug levels (>90%
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avoidances, Fig. 4a). The one-way ANOVA revealed a significant main effect of Drug
Group on avoidance levels on the first day of testing/retraining [F(5,50)=4.65, P<0.001].
Multiple group comparisons revealed that the HAL4 and HAL5 groups had a significantly
lower number of avoidances compared with the VEH group (LSD tests, all P values <0.05).
This potential carryover effect appears to be driven by two rats and was not seen in any
other experiment. There was no significant difference between groups on the second day of
retesting [F(5,50)=0.77, NS].
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On the challenge day when HAL sensitization was assessed, only the HAL5 group had
lower avoidance than the VEH group. One-way ANOVA showed the main effect of Drug
Group was marginally significant [F(5,50)=2.18, P=0.071]. Independent-samples t-tests
found that the HAL5 group had significantly lower avoidance levels compared with the
VEH group (P= 0.015, Fig. 4b). These findings suggest that repeated HAL treatment at a
relatively low dose induced a significantly enhanced response to HAL during the induction
phase. This enhanced sensitivity to HAL was still detectable 3 days later in rats that received
5 days of HAL injections.
Experiment 2: Effect of number of injections on olanzapine sensitization
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Figure 5a shows that the VEH group displayed a high level of avoidances over the 5 days of
testing, whereas rats injected with OLZ showed decreased avoidance levels after OLZ
injections. A repeated-measures ANOVA revealed significant main effects of Drug Group
[F(5,50)=19.09, P<0.001] and Session [F(4,200)=101.73, P<0.001] and a significant Group
× Session interaction [F(20,200)= 10.75, P<0.001], suggesting that the groups that had more
than one exposure to the drug (OLZ2, OLZ3, OLZ4, and OLZ5) showed a progressive
across-session decrease in avoidance levels (Fig. 5a). Avoidances recovered back to predrug
levels after 2 days of drug-free testing/retraining (>90% avoidances, Fig. 5a). There was no
significant difference on either day [day 1: F(5,50)=1.20, NS; day 2: F(5,50)=0.59, NS].
On the challenge day when OLZ sensitization was assessed, once again, only the OLZ5
group appeared to have lower avoidance than the VEH group. One-way ANOVA showed a
significant main effect of Drug Group on the number of avoidances [F(5,50)= 3.42, P<0.01]
and two-group comparisons showed that the OLZ5 group had significantly lower avoidances
than the VEH group (P<0.001, Fig. 5b). These findings suggest that repeated OLZ treatment
at a relatively low dose induced a significantly enhanced response to OLZ during the
induction phase. This enhanced sensitivity to OLZ was still detectable 3 days later in rats
that received 5 days of OLZ injections.
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Experiment 3: Dose-dependent effect of haloperidol on the strength of antipsychotic
sensitization effect
Although the VEH group maintained a high level of avoidances (>85% avoidances over 3
days of VEH exposure), those that were treated with HAL had lower avoidance levels
during the drug-treatment period (Fig. 6a). A repeated-measures ANOVA revealed
significant main effects of Drug Group [F(3,28)=67.95, P<0.001] and Session
[F(2,56)=27.76, P<0.001] and a significant Group × Session interaction [F(6,56)=3.04,
P<0.02], suggesting that the HAL groups showed a progressive across-session decrease in
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avoidance levels (Fig. 6a). During the two drug-free testing/retraining days, the avoidance
levels returned to predrug levels (>90% avoidances, Fig. 6a). There was no significant
difference on the first day of retesting [F(3,28)=2.79, P=0.059] or the second day of
retesting [F(3,28)=1.56, NS].

Author Manuscript

On the challenge day when HAL sensitization was assessed, one-way ANOVA showed a
significant main effect of Drug Group on the number of avoidances [F(2,21)=7.98,
P<0.005]. Post-hoc tests showed that the HAL 0.1 mg/kg group had significantly lower
levels of avoidance compared with the VEH group (Fig. 6b and c, P<0.05). The difference
between the HAL 0.05 mg/kg group and the VEH group was marginally significant
(P=0.051). To further examine the temporal course of this difference, we examined the 10trial block data. One-way ANOVAs showed significant group differences in all three blocks
(P values <0.05). Post-hoc tests showed that the HAL 0.1 mg/kg group had significantly
lower avoidances than the VEH group in all three blocks, whereas the HAL 0.05 mg/kg
group was significantly lower than the VEH group only on the block 3 (all P values <0.05).
These results suggest that HAL sensitization is dose-dependent, with the high dose and the
medium dose (to a lesser extent) inducing a strong sensitization, whereas the low dose does
not.
Experiment 4: Effect of olanzapine dose on the strength of antipsychotic sensitization
effect

Author Manuscript

Although the VEH group maintained a high level of avoidances (>70% avoidances over 3
days of VEH exposure), those that were treated with OLZ had lower avoidance levels during
the drug treatment period (Fig. 7a). A repeated-measures ANOVA revealed significant main
effects of Drug Group [F(3,28)=73.38, P<0.001] and Session [F(2,56)=62.40, P<0.001] and
a significant Group × Session interaction [F(6,56)=45.913, P=0.001], showing that the OLZ
groups showed a progressive across-session decrease in avoidance levels. One-way
ANOVAs showed that there was no significant difference among groups on either drug-free
testing/retraining day [day 1: F(3,28)=1.83, NS; day 2: F(3,28)= 0.14, NS]. All groups
returned to predrug levels (>90% avoidances) by the second day of retesting.
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On the challenge day when OLZ sensitization was assessed, both OLZ 2.0mg/kg and 1.0
mg/kg groups had lower avoidances than the VEH group. This observation was confirmed
by the statistical analysis. One-way ANOVA showed a significant main effect of Drug
Group [F(2,21)=8.86, P<0.002, Fig. 7b], and two-group comparisons indicated that both the
OLZ 2.0 mg/kg group and the OLZ 1.0 mg/kg group were significantly different from the
VEH group (P values <0.01). These results suggest that OLZ sensitization is dosedependent, with the medium and high doses inducing a robust sensitization, whereas the low
dose fails to do so.
Experiment 5: Effect of time interval between initial haloperidol exposure and re-exposure
on the strength of haloperidol sensitization
During the initial drug-treatment period, the VEH group maintained a high level of
avoidances (>80% avoidances over 3 days of exposure), whereas the HAL groups had
reduced avoidance levels. A repeated-measures ANOVA revealed significant main effects of
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Drug Group [F(5,42)= 1794.09, P<0.001] and Session [F(2,84)=22.53, P<0.001] and a
significant Group × Session interaction [F(10,84)= 2.70, P<0.01], suggesting that the HAL
groups showed a progressive across-session decrease in avoidance levels (Fig. 8a). There
was no significant difference between the VEH and HAL groups on the first or second
retesting day for any of the 4-, 10- or 17-day groups (all P values >0.05). All groups
returned to predrug levels by the retraining day (>90% avoidances, Fig. 8a).
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On the challenge test, there was a significant main effect of Drug Group (Fig. 8b and c,
F(1,42)=9.83, P<0.005), and a significant main effect of Interval [F(1,42)=6.30, P<0.005),
but no significant Group × Interval interaction [F(3,42)=0.008, NS]. Planned comparisons
showed that the HAL–HAL4 group had a significantly lower avoidance level than the VEH–
HAL4 group (P<0.05, Fig. 8b). However, the HAL–HAL10 group did not differ
significantly from the VEH–HAL10 group, whereas the difference between the VEH–
HAL17 and HAL–HAL17 groups approached significance (P=0.050). Further analysis
revealed that the two 17-day groups had significantly lower avoidance levels on the
challenge day than the 4-day and 10-day groups (all P values ≤ 0.05).
These results show that the time interval between the drug treatment and challenge test
(test–retest interval) plays a role in HAL sensitization. However, since there was no
significant interaction between interval and HAL, it appears that HAL sensitization did not
decrease over time and was maintained throughout the 17-day period.
Experiment 6: Effect of time interval between initial olanzapine exposure and re-exposure
on the strength of olanzapine sensitization
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During the initial drug-treatment period, the VEH group maintained a high level of
avoidances (>70% avoidances over 3 days of exposure), whereas the groups receiving OLZ
had lower avoidance levels. A repeated-measures ANOVA revealed significant main effects
of Drug Group [F(5,40)=797.76, P<0.000] and Session [F(2,80)= 31.69, P<0.000], but no
significant Group × Interval interaction [F(10,80)=1.74, P=0.087]. The OLZ groups did
show a progressive across-session decrease in avoidance levels (Fig. 9a). There was no
significant difference between the VEH and OLZ groups on either the first or second
retesting day (all P values >0.05). All groups returned to predrug levels by the retraining day
(>90% avoidances, Fig. 9a).
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On the challenge day, there was a significant main effect of Drug Group [F(1, 40)=25.47,
P<0.001], but no significant main effect of Interval [F(2,40)=1.28, NS] or Group × Interval
interaction [F(2,40)=1.62, NS]. Further analysis using planned comparisons showed that
there was a significant difference between the VEH–OLZ4 and OLZ–OLZ4 groups (P<0.05,
Fig. 9b). There was no significant difference between the VEH–OLZ10 and OLZ–OLZ10
groups, although it approached significance (P=0.055), whereas the difference between the
VEH–OLZ17 and OLZ17 groups was significant (P<0.01). These results show that
avoidance responding as well as OLZ sensitization did not change over time and was
maintained after 17 days.
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Discussion
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In the series of experiments, we investigated the impact of three parameters previously
implicated in the development of psychomotor sensitization of drugs of abuse (i.e. number
of exposures, length of interval, drug dose) on the induction and maintenance of
antipsychotic sensitization in the CAR model. We found that the three tested doses of HAL
and OLZ produced the classic sensitization pattern of progressively increased behavioral
effect during the induction phase, as characterized by a progressively-enhanced disruption of
conditioned avoidance responding across sessions. However, the sensitization effect during
the expression/maintenance phase (i.e. the drug-challenge test) was strongly affected by
various parameters. Sensitization induced by a relatively low dose of antipsychotics
(0.025mg/kg HAL and 0.5 mg/kg OLZ) was only apparent in rats that received treatment for
5 days. The groups that had 1–4 days of exposure did not have even slightly lower
avoidance levels on the challenge day; instead, their levels were no different from that of the
VEH group. These results suggest that the induction and maintenance of antipsychotic
sensitization may have different temporal courses. In the dose-dependence experiments, we
replicated the finding that a low dose of HAL or OLZ injected for 3 days was unable to
induce a long-term sensitization as assessed in the expression phase. In contrast, the medium
or high doses of HAL or OLZ were able to induce robust sensitization with just 3 days of
drug treatment. Both drug-induced sensitizations were dose-dependent, with higher doses
inducing stronger sensitization. Finally, the HAL (0.10 mg/kg) and OLZ (2.0 mg/kg)
sensitization effect was long-lasting: it was still apparent even 17 days after the last drug
treatment. The selected intervals (i.e. 4, 10, and 17) were not as critical a factor as drug dose
and number of exposures. It should be noted that although we examined these three
parameters in separate experiments, they do not operate in isolation. It is likely that these
parameters interact in determining the magnitude and strength of antipsychotic sensitization.
The above findings, when viewed together, are in support of this point.
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The present study demonstrated antipsychotic sensitization using a test paradigm that is
commonly used in psychomotor sensitization (Anagnostaras and Robinson, 1996; Pierce and
Kalivas, 1997; Robinson et al., 1998). It consists of an induction phase (i.e. repeated drug
treatment period) and an expression phase (i.e. challenge test) during which all animals are
tested under the same antipsychotic drug treatment. Antipsychotic-induced sensitization is
indicated by the higher inhibition of avoidance in the HAL-treated or OLZ-treated group
than the VEH group. From a learning and memory perspective, these two phases can be
characterized as the training (i.e. acquisition) and memory testing phases. Furthermore,
similar to a typical learning task (e.g. Morris water maze), the number of drug injections,
drug dose, and test–retest interval can be conceptualized as the number of learning trials
(sessions), learning intensity, and time interval between learning and memory tests in a
learning task (Domjan, 2005). Their impacts on the induction and maintenance of
antipsychotic sensitization can thus be understood, as all the three factors are known to
affect learning and memory. From this perspective, antipsychotics drugs can be viewed as
exogenous stimuli that impact on brain structure, brain functions, and behavior. The fact that
antipsychotic treatment itself induces a long-term potentiation, a molecular mechanism of
learning and memory is in support of this view (Centonze et al., 2004). Similar to other
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discrete stimuli, they can function as conditioned or unconditioned stimuli in an associative
learning paradigm. Indeed, our recent work provided evidence that HAL and OLZ can be
used as unconditioned stimuli in a drug–drug conditioning paradigm to alter behavioral
effects of other psychoactive drugs (Li et al., 2009a).
In experiments 5 and 6, we showed that sensitization was present after 17 days for both
HAL and OLZ, which is consistent with previous work showing that sensitization was seen
up to 22 days later in a catalepsy test (Barnes et al., 1990) and even 3 weeks after the last
drug treatment (Mead and Li, 2010). In the field of psychostimulant sensitization, it has been
shown that sensitization to a single dose of amphetamine can last as long as 12 weeks
(Robinson, 1984). Future research using longer intervals is needed to determine how long
antipsychotic sensitization can last.
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Antipsychotic sensitization appears to be a universal phenomenon associated with repeated
drug treatment. Besides the CAR model, it has been reported in a catalepsy test (Lanis and
Schmidt, 2001; Amtage and Schmidt, 2003; Klein and Schmidt, 2003), a phencyclidineinduced hyperlocomotion test (Sun et al., 2009; Zhang and Li, 2012), a prepulse inhibition
of acoustic startle procedure (Li et al., 2011), and an operant responding procedure (Varvel
et al., 2002), as well as for the metabolic effect (Boyda et al., 2012). This is not to suggest
that all antipsychotic drugs will induce a sensitization effect after repeated drug
administration. One exception is clozapine. For example, although repeated HAL and OLZ
induce sensitization in the CAR test, repeated clozapine induces tolerance (Li et al., 2010).
Clozapine-induced tolerance has also been observed in a drug discrimination task (Goudie et
al., 2007a, 2007b). Therefore, different antipsychotic drugs may have different intrinsic
properties linked to their unique receptor binding profiles and clinical effects.
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There appear to be a number of similarities between sensitization observed with drugs of
abuse and that in antipsychotic drugs. Behavioral sensitization, a widely studied
phenomenon associated with psychostimulants, is characterized by an augmented motorstimulant response to stimulants seen after repeated, intermittent treatment to a specific
compound (Paulson and Robinson, 1995). Historically, the term ‘behavioral sensitization’
has been associated with drugs of abuse; here we use ‘antipsychotic sensitization’ to refer to
the observation that (a) during repeated drug treatment, avoidance disruptive effects of HAL
and OLZ actually increase in magnitude (a within-group sensitization); and (b) during the
challenge test, there is an enhanced behavioral response to a drug due to prior exposure to
that drug (a between-group sensitization). Behavioral sensitization induced by drugs of
abuse is dependent upon a number of factors including interval, dose, and number of
exposures (Post and Contel, 1983), which were shown in this study also to be important to
antipsychotic sensitization. In this study, we found that antipsychotic sensitization, as
assessed in the CAR model required 5 days of treatment at a low dose to produce
sensitization, which contrasts with results from the behavioral sensitization literature, in
which behavioral sensitization could be seen after only one prior dose of the drug (Robinson
et al., 1982; Kalivas and Alesdatter, 1993; Vanderschuren et al., 1999; Grignaschi et al.,
2004). Although the sensitization seen with drugs of abuse may share similar properties to
sensitization seen with antipsychotics, such as dependency on specific parameters,
antipsychotic sensitization may be less robust than that seen with addictive substances.
Behav Pharmacol. Author manuscript; available in PMC 2016 February 17.

Swalve and Li

Page 12

Author Manuscript

So what are the possible neurobiological mechanisms involved in antipsychotic
sensitization? We speculate that it may have something to do with the drug-induced brain
changes (e.g. neuroplasticity) because of its learning-like and memory-like characteristics
(Konradi and Heckers, 2001). These changes thus might include elevations in the number
and sensitivity of neuroreceptors (e.g. D2 receptors; Samaha et al., 2007, 2008), changes in
immediate early gene expressions (e.g. c-fos, zif268, ΔFosB, Nguyen et al., 1992; Robertson
and Fibiger, 1992; Robertson et al., 1994; Grande et al., 2004), and associated intracellularsignaling pathways (e.g. DARPP-32, cAMP, and PKA phosphorylation in the striatopallidal
neurons, Bateup et al., 2008), or even adult neurogenesis (Kippin et al., 2005). Other
parametric work with antipsychotics also shows that dopamine turnover may play a role in
the development of sensitization (Csernansky et al., 1990). We also recently examined the
neurochemical basis of the antipsychotic sensitization induction in the CAR model and
found that induction of HAL sensitization may be directly mediated by 5-HT2A/2C blockadeinitiated neuroplasticity, whereas the induction of OLZ sensitization may be directly
mediated by D2/3 blockade-initiated neuroplasticity (Li et al., 2010). One important line of
research is to delineate how antipsychotics induce brain changes through these and other
receptor systems (e.g. 5-HT1A, D1, D4, etc.) and where these changes take place.
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Though our model uses a preclinical approach to determine the parameters of the
sensitization effect of antipsychotics, this model has the potential to be translated into
clinical research. The ability to generalize such an effect from preclinical to clinical models
has been validated in the past and allows for the possibility of exploring a lower dosage
regimen for patients in the future (Antelman and Gershon, 1998). The conventional clinical
approach to a dosing regimen is daily administration of a typically high dose of
antipsychotics to produce the dopamine D2 receptor occupancy that has been believed to be
necessary to diminish symptoms. Recent advances in pharmacology have shown that
continuous high D2 receptor occupancy from antipsychotics is not as critical as once thought
(Remington and Kapur, 2010). Drugs that produce only transient binding to the receptor
have been shown to be clinically effective in treating schizophrenia and the same behavioral
response can be maintained at lower levels of occupancy (Rabin and Siegel, 2010; Kapur et
al., 2000). The present study could be used to determine possible parameters of clinical
treatment to create dosing regimens that would lower the adverse side-effects of
antipsychotics as well as produce necessary symptom alleviation.
Conclusion
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Our study not only details the exact parameters involved in the antipsychotic sensitization
effect, but also chronicles some unexpected findings. The development of sensitization to
HAL and OLZ appears to be as robust as sensitization seen with drugs of abuse such as
cocaine and it is maintained over a long period of time. Antipsychotics require at least 5
days at a low dose to see a significant difference on the challenge day. However, at more
salient dosages, sensitization is present at even shorter intervals. Intriguingly, there seemed
to be no significant change over time in the strength of antipsychotic sensitization induced
by a high dose of HAL or OLZ. This study provides valuable information for future studies
on the mechanisms involved in the sensitization effect of antipsychotics but also has clinical
implications that extend beyond the preclinical realm.
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Fig. 1.

A schematic representation of the experimental procedure in experiments 1 and 2. HAL,
haloperidol; OLZ, olanzapine; VEH, vehicle.
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Fig. 2.

A schematic representation of the experimental procedure in experiments 3 and 4. HAL,
haloperidol; OLZ, olanzapine.
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Fig. 3.

A schematic representation of the experimental procedure in experiments 5 and 6.
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(a) Effect of repeated haloperidol (HAL) treatment (0.025 mg/kg, subcutaneously, 60 min)
on conditioned avoidance responding across sessions. Number of avoidance responses made
by the rats in the final training day (drug-free), 50 days of drug exposure, and two drug-free
retesting sessions are expressed as mean±SEM. Different groups of rats received either 0, 1,
2, 3, 4, or 5 days of HAL (*P<0.05). (b) Effect of number of drug exposure days on final
challenge day. All groups were injected with HAL (0.025 mg/kg) and avoidance responses
were measured (*P<0.05). VEH, vehicle.
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(a) Effect of repeated olanzapine (OLZ) treatment (0.5 mg/kg, subcutaneously, 60 min) on
conditioned avoidance responding across sessions. Number of avoidance responses made by
the rats in the final training day (drug-free), 5 days of drug exposure, and two drug-free
retesting sessions are expressed as mean±SEM. Different groups of rats received either 0, 1,
2, 3, 4, or 5 days of olanzapine (*P<0.05). (b) Effect of number of drug exposure days on
final challenge day. All groups were injected with OLZ (0.5 mg/kg) and avoidance
responses were measured (*P<0.05). VEH, vehicle.
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(a) Effect of repeated haloperidol (HAL) treatment (0.025, 0.05, or 0.1 mg/kg,
subcutaneously, 60 min) on conditioned avoidance responding across sessions. Number of
avoidance responses made by the rats on the final training day (drug-free), 3 days of drug
exposure, and two drug-free retesting sessions are expressed as mean±SEM (*P<0.05). (b)
Effect of dose on final challenge day. All groups were injected with HAL (0.025 mg/kg) and
avoidance responses were measured (*P<0.05). (c) Effect of dose on 10-trial blocks on
challenge day. VEH, vehicle.
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(a) Effect of repeated olanzapine (OLZ) treatment (0.5, 1.0, or 2.0 mg/kg, subcutaneously,
60 min) on conditioned avoidance responding across sessions. Number of avoidance
responses made by the rats on the final training day (drug-free), 3 days of drug exposure,
and two drug-free retesting sessions are expressed as mean±SEM (*P<0.05). (b) Effect of
dose on final challenge day. All groups were injected with OLZ (0.5 mg/kg) and avoidance
responses were measured (*P<0.05). VEH, vehicle.
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(a) Effect of repeated haloperidol (HAL) treatment (0.1 mg/kg, subcutaneously, 60 min) on
conditioned avoidance responding across sessions. Number of avoidance responses made by
the rats on the final training day (drug-free), 3 days of drug exposure, and two drug-free
retesting sessions are expressed as mean±SEM. Rats received either 1, 7, or 14 days of rest
according to their group and were then retested in the conditioned avoidance response boxes
(*P<0.05). (b) Effect of test–retest interval on final challenge day. All groups were injected
with HAL (0.025 mg/kg) and avoidance responses were measured (*P<0.05). (c) Effect of
dose on 10-trial blocks on challenge day. VEH, vehicle.
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Fig. 9.

(a) Effect of repeated olanzapine (OLZ) treatment (2.0 mg/kg, subcutaneously, 60 min) on
conditioned avoidance responding across sessions. Number of avoidance responses made by
the rats in the final training day (drug-free), 3 days of drug exposure, and two drug-free
retesting sessions are expressed as mean±SEM. Rats received either 1, 7, or 14 days of rest
according to their group and were then retested in the conditioned avoidance response boxes
(*P<0.05). (b) Effect of test–retest interval on final challenge day. All groups were injected
with OLZ (0.5 mg/kg) and avoidance responses were measured (*P<0.05).
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